Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Aug;235(8):2303-2314.
doi: 10.1007/s00213-018-4926-4. Epub 2018 May 22.

Folic Acid/Methylfolate for the Treatment of Psychopathology in Schizophrenia: A Systematic Review and Meta-Analysis

Affiliations
Meta-Analysis

Folic Acid/Methylfolate for the Treatment of Psychopathology in Schizophrenia: A Systematic Review and Meta-Analysis

Kenji Sakuma et al. Psychopharmacology (Berl). .

Abstract

Rationale: This study aims to examine whether folate/folic acid/methylfolate/folinic acid supplemented to antipsychotics (FA + AP) is beneficial in schizophrenia treatment.

Objective: We conducted a comprehensive systematic review and meta-analysis of double-blind, placebo-controlled, randomized clinical trials (RCTs) of FA + AP for schizophrenia.

Methods: The primary outcome was an improvement in total symptoms. Other outcomes were psychopathology subscales (positive, negative, general, and depressive symptoms), discontinuation due to all-cause and adverse events, and individual adverse events. The meta-analysis evaluated the effect size based on a random-effects model.

Results: Although we included ten RCTs with 925 patients in total (seven folic acid RCTs (n = 789), two methylfolate RCTs (n = 96), and one folinic acid RCT (n = 40)) in the systematic review, only seven RCTs were included in the meta-analysis. Pooled FA + AP treatments were not superior to placebo + AP in the improvement of total (N = 7, n = 340; standardized mean difference (SMD) = - 0.20, 95% confidence interval (CI) = - 0.41, 0.02, p = 0.08, I2 = 0%), positive, general, or depressive symptoms. Pooled FA + AP treatments were more effective than placebo + AP for negative symptoms (N = 5, n = 281; SMD = -0.25, 95% CI = -0.49, -0.01, p = 0.04, I2 = 0%). Although pooled FA + AP treatments were associated with a lower incidence of serious adverse events than placebo treatments (N = 4, n = 241; risk ratio = 0.32, 95% CI = 0.12-0.82, p = 0.02, I2 = 0%; number needed to harm = not significant), there were no significant differences in other safety outcomes between both treatments.

Conclusions: Our findings suggest that pooled FA + AP treatment improves negative symptoms in schizophrenia patients. Moreover, this treatment was well tolerated. However, because our results might exhibit a small-study effect, future studies with a larger sample should be conducted to obtain more robust results.

Keywords: Folic acid; Meta-analysis; Methylfolate; Negative symptoms; Schizophrenia; Systematic review.

Comment in

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Schizophr Bull. 2014 Sep;40(5):1154-63 - PubMed
    1. Schizophr Res. 2011 Apr;127(1-3):41-5 - PubMed
    1. Biol Psychiatry. 2006 Aug 1;60(3):265-9 - PubMed
    1. Acta Psychiatr Scand. 1977 Apr;55(4):299-308 - PubMed
    1. Mol Psychiatry. 2018 Feb;23(2):316-322 - PubMed

MeSH terms

Feedback